Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

Golimumab

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

Yes

Post-marketing information

Dear Healthcare Professional Letters

Subsidy Information and Financing Scheme

Medical Assistance Fund

Active ingredient: Golimumab

General information

Subsidy Information and Financing Scheme

[MAF] Golimumab (Simponi) Prefilled Syringe 50 mg/0.5 mL, 100 mg/mL

  1. Additional clinical criteria applies

  2. Treatment of adult patients with rheumatoid arthritis

  3. Treatment of adult patients with ankylosing spondylitis

  4. Treatment of adult patients with psoriatic arthritis

  5. Treatment of adult patients with non-radiographic axial spondyloarthritis (axSpA).

  6. Treatment of adult patients with ulcerative colitis

View legend

Drug Guidance for Subsidy

18/01/2021 Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis (opens in new tab)

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Golimumab 50 mg/0.5 ml and 100 mg/ml pre-filled syringes in line with their registered indications for treating adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis.

Subsidy status

[R] Golimumab 50mg/0.5ml and 100 mg/ml pre-filled syringes are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

[R] Golimumab should be used in line with the clinical criteria in the checklists for MAF applications for anti-TNFα biologics.

[NR] MAF subsidy does not apply to golimumab 12.5mg/1ml concentrate solution for infusion formulation.

View legend

Post Marketing Information

DHCPL 03/03/2023 SIMPONI (golimumab) 50 mg and 100 mg: Important Changes to the Patient Information Leaflet (PIL) for the SmartJect (pre-filled pen) (opens in new tab)

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Simponi Prefilled Syringe 50 mg/0.5 mL

  1. Ng Teng Fong General Hospital

  2. National University Hospital

  3. Sengkang General Hospital

  4. Singapore General Hospital

  5. Tan Tock Seng Hospital

  6. Woodlands Health Campus

Simponi Prefilled Syringe 100 mg/mL

  1. Singapore General Hospital

  2. Tan Tock Seng Hospital

List of monographs containing this active ingredient

Golimumab [Simponi]